Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx
Danielle L. Gainor(Michigan Medicine), Andrew G. Shuman(University of Michigan), Mark E. Prince(University of Michigan), Jeremy M. G. Taylor(RAND Corporation), Carol R. Bradford(The Ohio State University), Emily L. Bellile(University of Michigan), Matthew E. Spector(Michigan Medicine), Emily Marchiano(Michigan Medicine), Norman D. Hogikyan(Michigan Medicine), Francis P. Worden(Georgetown University), Gregory T. Wolf(University of Michigan), Avraham Eisbruch(University of Michigan–Ann Arbor)
Cited by 8
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Validation of an instrument to measure voice-related quality of life (V-RQOL)
|Journal of Voice|1999|1.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653